Jersey Leads Groundbreaking Global Heart Failure Trial Using Wearable Technology

Jersey has become the first place in the world to launch a pioneering clinical trial investigating whether intravenous iron treatment can improve the daily lives of people living with heart failure by increasing their physical activity.

The study has begun with 10 participants, who have been randomly assigned to receive either an iron infusion or a placebo. Neither the patients nor the clinical team know which treatment has been given until the trial concludes, ensuring the results remain unbiased.

Throughout the 12-week study, participants wear a smart ring and a sensor attached to their leg, allowing researchers to continuously monitor indicators such as heart rate, standing time and walking activity. The information is securely transmitted through a smartphone app, providing a far more detailed picture of patients' day-to-day health than traditional assessment methods.

Dr Aaron Henry, a cardiologist at Jersey General Hospital and Research Fellow at the University of Oxford, said the trial marks a significant step forward in how heart failure research is carried out.

"Traditionally, we've measured exercise capacity using a six-minute walking test before treatment and again 12 weeks later," he explained. "While useful, that only captures a brief moment in time and can be influenced by factors such as sleep, weather or even whether someone has had a coffee that morning."

He said the new approach allows researchers to monitor patients around the clock for the entire duration of the trial, offering a much more accurate understanding of how treatment affects everyday life.

Although the wearable devices transmit data in real time, researchers will not analyse the information until the trial has finished to preserve the integrity of the study.

Participants will undergo further clinical assessments after the 12-week monitoring period.

The project is expected to recruit between 100 and 150 people over the next two to three years, with new participants joining the study each month.

Digital Jersey has committed £240,000 to fund the trial through a government-backed accelerator programme supporting technology-led innovation in health and social care.

Dr Henry said Jersey's healthcare system provides an ideal environment for conducting cutting-edge research.

"Jersey offers a unique opportunity to answer an important clinical question while also demonstrating how digital technology can transform cardiology research," he said. "We believe this approach could help shape the future of heart failure trials around the world."